Social Media Ideas for Novartis

<![CDATA[Novartis Announces $105 Million Collaborative Agreement with Antares Therapeutics]]>

<![CDATA[Novartis to Acquire Myricx Bio for $1.1 Billion]]>

Novartis to acquire ADC developer in a deal worth up to $1.5B

The deal hands over two ADCs with a different mechanism of action targeting cell growth, and marks Novartis' entry into ADC development.

Novartis’ strategy in 2026: rebuilding the pipeline after Entresto 

Find out what Novartis' pipeline strategy since it spun off its biosimilars and generics business Sandoz, and engage in intensive dealmaking. The post Novartis’ strategy in 2026: r...

A $1B Acquisition Gives Novartis a Way to Stand Out in Crowded Area of Cancer

Myricx Bio brings to Novartis antibody drug conjugates with a novel cancer-killing payload called an NMT inhibitor. Novartis says Myricx’s drugs could have advantages over currentl...

<![CDATA[Novartis to Layoff 322 NJ Employees: Report]]>

Novartis' phase 1/2 win tees up regulatory talks about dystrophy drug from $12B Avidity takeover

Novartis has reported a phase 1/2 win for one of the jewels of its $12 billion Avidity Biosciences buyout, setting the Swiss drugmaker up to talk to global regulatory agencies abou...

Novartis pays Antares $105M to illuminate undruggable cancer targets

Novartis is paying Antares Therapeutics $105 million upfront in a deal worth up to $1.9 billion to generate small molecules against historically undruggable oncology targets.

Novartis to pay $1.1B upfront for UK biotech Myricx to expand the pharma's ADC pipeline

Novartis is pushing deeper into antibody-drug conjugate development, paying $1.1 billion upfront to buy Myricx Bio for a pipeline based on a novel payload.

Novartis to Acquire Myricx Bio for Up to $1.5B, Adding Cancer-Fighting ADC Payload Platform

Myricx Bio specializes in developing ADCs that use N-myristoyltransferase inhibitor (NMTi) payloads, an approach designed to deliver a differentiated cancer-killing payload directl...

Novartis: 'Hold' On Continued Generic Erosion And Need For H2 2026 Catalysts

Novartis sticks 2nd deal with molecular glue biotech Orionis, this one worth up to $1.4B

Novartis has stuck on a second deal with Orionis Biosciences, this time handing $40 million upfront to the molecular glue biotech to work on “challenging therapeutic targets across...

<![CDATA[Pharma M&A Roundup: AstraZeneca Enters License Deal with Dizal Pharmaceutical, Chai Discovery Enters Col...

<![CDATA[Pharmaceutical Executive Daily: Roche and Nurix Therapeutics Announce Global Collaboration]]>

Antares gets $105M from Novartis for new cancer drugs

Adam Friedman, CEO of the Scorpion Therapeutics spinout, said the deal helps both companies accelerate research "faster than either of us could alone."

<![CDATA[The Origins of Nuvation Bio’s Deal with Daichii Sankyo for the Rights to Safusidenib in Japan]]>

Novartis ‘always looking’ for further ways to shuttle drugs to brain despite run of recent deals

Novartis may be launching an array of vehicles to shuttle drugs across the blood-brain barrier, but executives told Fierce the Swiss pharma is “always looking” for new ways to trav...

<![CDATA[GSK Enters $10.6 Billion Agreement to Acquire Nuvalent Inc. ]]>

Novartis RNA drug acquired in $12B Avidity deal notches a trial win

The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.

<![CDATA[Novavax's Strategy Across Commercial, R&D, and Partnerships]]>

<![CDATA[Roche Enters $2.3 Billion Global Collaboration with Nurix Therapeutics to Co-Develop and Co-Commercialize Be...

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Utebzi and Capvaxive]]>

<![CDATA[Nuvation Bio’s Global Strategy]]>

<![CDATA[Vertex to Acquire Crinetics Pharmaceuticals for $10 Billion]]>